Mr Richard Godfrey Chief Executive Officer
Richard Godfrey joined BerGenBio as Chief Executive Officer in 2008.
He has more than 25 years’ industry experience leading many international drug development and commercialisation partnerships. Formerly he served as Chief Executive Officer of Aenova Inc., a specialist biopharmaceutical company. Prior to this he was the Managing Director of DCC Healthcare Ltd and previously he held positions of increasing responsibility at Catalant, Eli Lilly and Reckitt Benckiser in R&D and commercial roles.
He qualified as a Pharmacist from Liverpool University and received his M.B.A. from Bath University.
Prof James Lorens Chief Scientific Officer
Professor James Lorens is the co-founder of BerGenBio, serves as the company’s Chief Scientific Officer and is also a Professor at the Department of Biomedicine at the University of Bergen.
On completing his postdoctoral research studies at Stanford University he joined Rigel Inc., a San Francisco based biotechnology company, as a founding scientist and research director. Prof. Lorens has managed several large scientific collaborations in cancer research and development with major pharmaceutical and biotechnology companies.
He leads a large internationally active academic research laboratory comprising 22 researchers. His group is active in EMT, angiogenesis and cancer research. Prof. Lorens is an author of more than 70 peer-reviewed articles and patents.
Dr Murray Yule Clinical Development Officer
Dr Murray Yule joined BerGenBio in 2011 and serves as Clinical Development Officer.
Since 1998, he has gained extensive experience in oncology clinical development supervising multiple early phase clinical studies of novel anticancer products, as well as planning and executing global development strategies for several anticancer drugs for top-ten pharmaceutical companies. His work has led to licensing approvals for novel tubulin binders in solid tumors and epigenetic therapies in acute leukemia.
He completed his medical training in oncology at Addenbrookes Hospital, Cambridge and holds a PhD in experimental pharmacology.
Mr Petter Nielsen Chief Financial Officer
Petter Nielsen joined BerGenBio in 2015 as CFO.
He has extensive experience related to mergers and acquisitions, IPOs, valuation and IFRS from Ernst & Young where he has worked in the Transaction Advisory Services group. Prior to joining BerGenBio, he held the position of CFO at GexCon, an R&D company that developed into an international group of companies focusing on commercial products and services.
He obtained an MSc in Auditing and an MSc in Economics and Business Administration, both from the Norwegian School of Economics.
Mrs Viki Wills Director of Clinical Operations
Viki Wills joined BerGenBio in 2016 and serves as Director of Clinical Operations, based in Oxford, UK.
She brings over 30 years’ experience in the management of clinical programmes from pharma, biotech and CRO companies across a number of therapeutic areas and phases, more recently focused on oncology.
She qualified as a Pharmacist from Bath University and completed her post-graduate registration in Bristol, UK.
Dr Anthony Brown Director of Research
Dr Anthony Brown joined BerGenBio as Research Director in October 2015.
He has over 25 years of experience in the drug discovery of both small molecules and biological therapeutics. He has managed strategic alliances with Pharma and Biotech and lead several novel programmes in Oncology, from early research through to clinical studies.
Previously he has held Senior Management and Director level positions at British Biotech, OSI Pharmaceuticals, Piramed Pharma, Cancer Research Technology and more recently at CellCentric.
He completed his doctorate from the University of Oxford in 1993 and MBA from Oxford Brookes University in 2008.
Dr Endre Kjærland Associate Director of IP and Contracts
Dr Endre Kjærland joined BerGenBio AS in 2011 and is now head of intellectual property, quality systems and contracts.
Prior to joining BerGenBio, he has gained more than 10 years of experience in academic science and supervision.
He completed a MSc in molecular biology and PhD in biochemistry from the University of Bergen.
Dr Julia Schölermann Associate Director BD & Partnering
Dr Julia Schoelermann joined BerGenBio in 2015. She is responsible for managing external academic collaborations including Investigator Initiated Trials.
She brings 10 years of hands-on laboratory and academic supervision experience from top European research institutions.
She holds an MSc in biotechnology and biophysics from the University of Heidelberg, Germany, a PhD in cell biology from the University of Bergen, Norway, and a dual-degree MBA from Brown University, USA, and ie business school in Madrid, Spain.